Recent Approaches on Oncolytic Viruses, Aptamers, TTFields and Personalized Treatment used for the Management of Glioblastoma: A Comprehensive Review


如何引用文章

全文:

详细

Glioblastoma (GB) remains a formidable challenge in oncology, with current treatment approaches providing only marginal improvements in patient outcomes. Despite significant advances in understanding its molecular and genetic characteristics, median survival for untreated patients remains distressingly low, emphasizing the urgent need for novel therapeutic strategies. This review comprehensively examines the standard first-line treatments for GB, including surgery, concomitant radio-chemotherapy, and maintenance chemotherapy, while highlighting the limitations of these approaches. Consequently, we explore emerging novel therapeutic modalities such as Oncolytic Viral Therapy with genetically modified oncolytic viruses that enhance the capabilities of antigen- presenting cells. These cells migrate to lymph nodes to recruit cytotoxic CD8+ T lymphocytes, directing them to the site of infection where they eradicate cells that promote tumour growth. Aptamer-based therapies, such as GMT-3, AS1411, GS24, GMT8, and Gint4.T, which exhibit specificity for their biological targets and can act as drug transporters by facilitating receptor-mediated transcytosis within the endothelial cells of the blood-brain barrier, thus improving drug delivery. Tumour-treating fields (TTFields) that have shown increased overall survival rates in patients. Personalized genomic medicine, driven by biomarkers, which provokes immune responses tailored to the tumour’s specific antigens, thereby customizing patient-specific treatments to improve effectiveness. By synthesizing current evidence and recent breakthroughs, we underscore the potential use of advancing novel therapies to address the unmet clinical needs of GB patients and ultimately enhance their overall survival and quality of life.

作者简介

Archna Singh

Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute)

编辑信件的主要联系方式.
Email: info@benthamscience.net

Anmol Kanda

Department of Pharmacology, Noida Institute of Engineering and Technology (Pharmacy Institute)

Email: info@benthamscience.net

Jyoti Kanda

Department of Behavioural Science (Psychology), Jamia Millia Islamia

Email: info@benthamscience.net

参考

  1. Grochans, S.; Cybulska, A.M.; Simińska, D.; Korbecki, J.; Kojder, K.; Chlubek, D.; Baranowska-Bosiacka, I. Epidemiology of glioblastoma multiforme–literature review. Cancers , 2022, 14(10), 2412. doi: 10.3390/cancers14102412 PMID: 35626018
  2. Rončević, A.; Koruga, N.; Soldo, K.A.; Rončević, R.; Rotim, T.; Šimundić, T.; Kretić, D.; Perić, M.; Turk, T.; Štimac, D. Personalized treatment of glioblastoma: Current state and future perspective. Biomedicines, 2023, 11(6), 1579. doi: 10.3390/biomedicines11061579 PMID: 37371674
  3. Gilard, V.; Tebani, A.; Dabaj, I.; Laquerrière, A.; Fontanilles, M.; Derrey, S.; Marret, S.; Bekri, S. Diagnosis and management of glioblastoma: A comprehensive perspective. J. Pers. Med., 2021, 11(4), 258. doi: 10.3390/jpm11040258 PMID: 33915852
  4. Kim, M.; Ladomersky, E.; Mozny, A.; Kocherginsky, M.; O’Shea, K.; Reinstein, Z.Z.; Zhai, L.; Bell, A.; Lauing, K.L.; Bollu, L.; Rabin, E.; Dixit, K.; Kumthekar, P.; Platanias, L.C.; Hou, L.; Zheng, Y.; Wu, J.; Zhang, B.; Hrachova, M.; Merrill, S.A.; Mrugala, M.M.; Prabhu, V.C.; Horbinski, C.; James, C.D.; Yamini, B.; Ostrom, Q.T.; Johnson, M.O.; Reardon, D.A.; Lukas, R.V.; Wainwright, D.A. Glioblastoma as an age-related neurological disorder in adults. Neurooncol. Adv., 2021, 3(1), vdab125. doi: 10.1093/noajnl/vdab125 PMID: 34647022
  5. Touat, M.; Idbaih, A.; Sanson, M.; Ligon, K.L. Glioblastoma targeted therapy: Updated approaches from recent biological insights. Ann. Oncol., 2017, 28(7), 1457-1472. doi: 10.1093/annonc/mdx106 PMID: 28863449
  6. Louis, D.N.; Perry, A.; Wesseling, P.; Brat, D.J.; Cree, I.A.; Figarella-Branger, D.; Hawkins, C.; Ng, H.K.; Pfister, S.M.; Reifenberger, G.; Soffietti, R.; von Deimling, A.; Ellison, D.W. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-oncol., 2021, 23(8), 1231-1251. doi: 10.1093/neuonc/noab106 PMID: 34185076
  7. Holland, E.C.; Ene, C.I. Personalized medicine for gliomas. Surg. Neurol. Int., 2015, 6(2)(Suppl. 1), 89. doi: 10.4103/2152-7806.151351 PMID: 25722938
  8. Limam, S.; Missaoui, N.; Abdessayed, N.; Mestiri, S.; Selmi, B.; Mokni, M.; Yacoubi, M.T. Prognostic significance of MGMT methylation and expression of MGMT, P53, EGFR, MDM2 and PTEN in glioblastoma multiforme. Ann. Biol. Clin. (Paris), 2019, 77(3), 307-317. doi: 10.1684/abc.2019.1448 PMID: 31131831
  9. DeCordova, S.; Shastri, A.; Tsolaki, A.G.; Yasmin, H.; Klein, L.; Singh, S.K.; Kishore, U. Molecular heterogeneity and immunosuppressive microenvironment in glioblastoma. Front. Immunol., 2020, 11, 1402. doi: 10.3389/fimmu.2020.01402 PMID: 32765498
  10. Shukla, G.; Alexander, G.S.; Bakas, S.; Nikam, R.; Talekar, K.; Palmer, J.D.; Shi, W. Advanced magnetic resonance imaging in glioblastoma: A review. Chin. Clin. Oncol, 2017, 6(4), 40. doi: 10.21037/cco.2017.06.28 PMID: 28841802
  11. Wilhelmsson, U.; Eliasson, C.; Bjerkvig, R.; Pekny, M. Loss of GFAP expression in high-grade astrocytomas does not contribute to tumor development or progression. Oncogene, 2003, 22(22), 3407-3411. doi: 10.1038/sj.onc.1206372 PMID: 12776191
  12. Jung, C.S.; Foerch, C.; Schänzer, A.; Heck, A.; Plate, K.H.; Seifert, V.; Steinmetz, H.; Raabe, A.; Sitzer, M. Serum GFAP is a diagnostic marker for glioblastoma multiforme. Brain, 2007, 130(12), 3336-3341. doi: 10.1093/brain/awm263 PMID: 17998256
  13. Czarnywojtek, A.; Borowska, M.; Dyrka, K.; Van Gool, S.; Sawicka-Gutaj, N.; Moskal, J.; Kościński, J.; Graczyk, P.; Hałas, T.; Lewandowska, A.M.; Czepczyński, R.; Ruchała, M. Glioblastoma multiforme: The latest diagnostics and treatment techniques. Pharmacology, 2023, 108(5), 423-431. doi: 10.1159/000531319 PMID: 37459849
  14. Stupp, R.; Mason, W.P.; van den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; Curschmann, J.; Janzer, R.C.; Ludwin, S.K.; Gorlia, T.; Allgeier, A.; Lacombe, D.; Cairncross, J.G.; Eisenhauer, E.; Mirimanoff, R.O. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 2005, 352(10), 987-996. doi: 10.1056/NEJMoa043330 PMID: 15758009
  15. McBain, C.; Lawrie, T.A.; Rogozińska, E.; Kernohan, A.; Robinson, T.; Jefferies, S. Treatment options for progression or recurrence of glioblastoma: A network meta-analysis. Cochrane Database Syst. Rev., 2021, 5(1), CD013579. PMID: 34559423
  16. Mohan, G.; Ayisha, H.T.P.; Narayanasamy, A.; Vellingiri, B. Recent advances in radiotherapy and its associated side effects in cancer: A review. J. Basic Appl. Zool., 2019, 80(1), 1-0.
  17. Liu, M.; Thakkar, J.P.; Garcia, C.R.; Dolecek, T.A.; Wagner, L.M.; Dressler, E.V.M.; Villano, J.L. National cancer database analysis of outcomes in pediatric glioblastoma. Cancer Med., 2018, 7(4), 1151-1159. doi: 10.1002/cam4.1404 PMID: 29532996
  18. Nowak, B.; Rogujski, P.; Janowski, M.; Lukomska, B.; Andrzejewska, A. Mesenchymal stem cells in glioblastoma therapy and progression: How one cell does it all. Biochim. Biophys. Acta Rev. Cancer, 2021, 1876(1), 188582. doi: 10.1016/j.bbcan.2021.188582 PMID: 34144129
  19. Angom, R.S.; Nakka, N.M.R.; Bhattacharya, S. Advances in glioblastoma therapy: An update on current approaches. Brain Sci., 2023, 13(11), 1536. doi: 10.3390/brainsci13111536 PMID: 38002496
  20. Gujar, S.; Bell, J.; Diallo, J.S. SnapShot: Cancer immunotherapy with oncolytic viruses. Cell, 2019, 176(5), 1240-1240.e1. doi: 10.1016/j.cell.2019.01.051 PMID: 30794777
  21. Asija, S.; Chatterjee, A.; Yadav, S.; Chekuri, G.; Karulkar, A.; Jaiswal, A.K.; Goda, J.S.; Purwar, R. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Int. Rev. Immunol., 2022, 41(6), 582-605. doi: 10.1080/08830185.2022.2101647 PMID: 35938932
  22. Ali, S.; Xia, Q.; Muhammad, T.; Liu, L.; Meng, X.; Bars-Cortina, D.; Khan, A.A.; Huang, Y.; Dong, L. Glioblastoma therapy: Rationale for a mesenchymal stem cell-based vehicle to carry recombinant viruses. Stem Cell Rev. Rep., 2022, 18(2), 523-543. doi: 10.1007/s12015-021-10207-w PMID: 34319509
  23. Rong, L.; Li, N.; Zhang, Z. Emerging therapies for glioblastoma: Current state and future directions. J. Exp. Clin. Cancer Res., 2022, 41(1), 142. doi: 10.1186/s13046-022-02349-7 PMID: 35428347
  24. Blitz, S.E.; Kappel, A.D.; Gessler, F.A.; Klinger, N.V.; Arnaout, O.; Lu, Y.; Peruzzi, P.P.; Smith, T.R.; Chiocca, E.A.; Friedman, G.K.; Bernstock, J.D. Tumor-associated macrophages/microglia in glioblastoma oncolytic virotherapy: A double-edged sword. Int. J. Mol. Sci., 2022, 23(3), 1808. doi: 10.3390/ijms23031808 PMID: 35163730
  25. Zhou, C.; Chen, Q.; Chen, Y.; Qin, C.F. Oncolytic Zika virus: New option for glioblastoma treatment. DNA Cell Biol., 2023, 42(6), 267-273. doi: 10.1089/dna.2022.0375 PMID: 36350682
  26. Marelli, G.; Howells, A.; Lemoine, N.R.; Wang, Y. Oncolytic viral therapy and the immune system: A double-edged sword against cancer. Front. Immunol., 2018, 9, 866. doi: 10.3389/fimmu.2018.00866 PMID: 29755464
  27. Markert, J.M.; Razdan, S.N.; Kuo, H.C.; Cantor, A.; Knoll, A.; Karrasch, M.; Nabors, L.B.; Markiewicz, M.; Agee, B.S.; Coleman, J.M.; Lakeman, A.D.; Palmer, C.A.; Parker, J.N.; Whitley, R.J.; Weichselbaum, R.R.; Fiveash, J.B.; Gillespie, G.Y. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Mol. Ther., 2014, 22(5), 1048-1055. doi: 10.1038/mt.2014.22 PMID: 24572293
  28. Kicielinski, K.P.; Chiocca, E.A.; Yu, J.S.; Gill, G.M.; Coffey, M.; Markert, J.M. Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol. Ther., 2014, 22(5), 1056-1062. doi: 10.1038/mt.2014.21 PMID: 24553100
  29. Desjardins, A.; Gromeier, M.; Herndon, J.E., II; Beaubier, N.; Bolognesi, D.P.; Friedman, A.H.; Friedman, H.S.; McSherry, F.; Muscat, A.M.; Nair, S.; Peters, K.B.; Randazzo, D.; Sampson, J.H.; Vlahovic, G.; Harrison, W.T.; McLendon, R.E.; Ashley, D.; Bigner, D.D. Recurrent glioblastoma treated with recombinant poliovirus. N. Engl. J. Med., 2018, 379(2), 150-161. doi: 10.1056/NEJMoa1716435 PMID: 29943666
  30. Mehta, A.M.; Sonabend, A.M.; Bruce, J.N. Convection-enhanced delivery. Neurotherapeutics, 2017, 14(2), 358-371. doi: 10.1007/s13311-017-0520-4 PMID: 28299724
  31. Bauzon, M.; Hermiston, T. Armed therapeutic viruses: A disruptive therapy on the horizon of cancer immunotherapy. Front. Immunol., 2014, 5, 74. doi: 10.3389/fimmu.2014.00074 PMID: 24605114
  32. Shah, S. Novel therapies in glioblastoma treatment: Review of glioblastoma; Current treatment options; and novel oncolytic viral therapies. Med. Sci., 2023, 12(1), 1. doi: 10.3390/medsci12010001 PMID: 38249077
  33. Hsu, E.; Keene, D.; Ventureyra, E.; Matzinger, M.A.; Jimenez, C.; Wang, H.S.; Grimard, L. Bone marrow metastasis in astrocytic gliomata. J. Neurooncol., 1998, 37(3), 285-293. doi: 10.1023/A:1005909127196 PMID: 9524086
  34. Hamad, A.; Yusubalieva, G.M.; Baklaushev, V.P.; Chumakov, P.M.; Lipatova, A.V. Recent developments in glioblastoma therapy: oncolytic viruses and emerging future strategies. Viruses, 2023, 15(2), 547. doi: 10.3390/v15020547 PMID: 36851761
  35. Chatterjee, D.; Bhattacharya, S.; Kumari, L.; Datta, A. Aptamers: Ushering in new hopes in targeted glioblastoma therapy. J. Drug Target., 2024, 32(9), 1005-1028. doi: 10.1080/1061186X.2024.2373306 PMID: 38923419
  36. Nakhjavani, M.; Shigdar, S. Future of PD-1/PD-L1 axis modulation for the treatment of triple-negative breast cancer. Pharmacol. Res., 2022, 175, 106019. doi: 10.1016/j.phrs.2021.106019 PMID: 34861397
  37. Glioblastoma treatment with irradiation and Olaptesed Pegol (NOX-A12). NC Patent T04121455
  38. Li, Z.; Fu, X.; Huang, J.; Zeng, P.; Huang, Y.; Chen, X.; Liang, C. Advances in screening and development of therapeutic aptamers against cancer cells. Front. Cell Dev. Biol., 2021, 9, 662791. doi: 10.3389/fcell.2021.662791 PMID: 34095130
  39. Giles, B.; Samarasinghe, R.M.; Shigda, S. Rising to the challenge: Recent aptamer-conjugate success in treating glioblastoma. Aptamers (Oxf.), 2022, 6, 28-37.
  40. Sefah, K.; Shangguan, D.; Xiong, X.; O’Donoghue, M.B.; Tan, W. Development of DNA aptamers using Cell-SELEX. Nat. Protoc., 2010, 5(6), 1169-1185. doi: 10.1038/nprot.2010.66 PMID: 20539292
  41. Mahmoudian, F.; Ahmari, A.; Shabani, S.; Sadeghi, B.; Fahimirad, S.; Fattahi, F. Aptamers as an approach to targeted cancer therapy. Cancer Cell Int., 2024, 24(1), 108. doi: 10.1186/s12935-024-03295-4 PMID: 38493153
  42. Ruscito, A.; DeRosa, M.C. Small-molecule binding aptamers: Selection strategies, characterization, and applications. Front Chem., 2016, 4, 14. doi: 10.3389/fchem.2016.00014 PMID: 27242994
  43. Han, J.; Gao, L.; Wang, J.; Wang, J. Application and development of aptamer in cancer: From clinical diagnosis to cancer therapy. J. Cancer, 2020, 11(23), 6902-6915. doi: 10.7150/jca.49532 PMID: 33123281
  44. Wang, R.E.; Wu, H.; Niu, Y.; Cai, J. Improving the stability of aptamers by chemical modification. Curr. Med. Chem., 2011, 18(27), 4126-4138. doi: 10.2174/092986711797189565 PMID: 21838692
  45. Henri, J.L.; Nakhjavani, M.; McCoombe, S.; Shigdar, S. Cytotoxic effects of aptamer-doxorubicin conjugates in an ovarian cancer cell line. Biochimie, 2023, 204, 108-117. doi: 10.1016/j.biochi.2022.09.005 PMID: 36155804
  46. Fu, W.; You, C.; Ma, L.; Li, H.; Ju, Y.; Guo, X.; Shi, S.; Zhang, T.; Zhou, R.; Lin, Y. Enhanced efficacy of temozolomide loaded by a tetrahedral framework DNA nanoparticle in the therapy for glioblastoma. ACS Appl. Mater. Interfaces, 2019, 11(43), 39525-39533. doi: 10.1021/acsami.9b13829 PMID: 31601097
  47. Bayrac, A.T.; Sefah, K.; Parekh, P.; Bayrac, C.; Gulbakan, B.; Oktem, H.A.; Tan, W. In vitro selection of DNA aptamers to glioblastoma multiforme. ACS Chem. Neurosci., 2011, 2(3), 175-181. doi: 10.1021/cn100114k PMID: 21892384
  48. Luo, Z.; Yan, Z.; Jin, K.; Pang, Q.; Jiang, T.; Lu, H.; Liu, X.; Pang, Z.; Yu, L.; Jiang, X. Precise glioblastoma targeting by AS1411 aptamer-functionalized poly (l-γ-glutamylglutamine)–paclitaxel nanoconjugates. J. Colloid Interface Sci., 2017, 490, 783-796. doi: 10.1016/j.jcis.2016.12.004 PMID: 27988470
  49. Zeng, Y.; Zhao, L.; Li, K.; Ma, J.; Chen, D.; Liu, C.; Zhan, W.; Zhan, Y. Aptamer-functionalized nanoplatforms overcoming temozolomide resistance in synergistic chemo/photothermal therapy through alleviating tumor hypoxia. Nano Res., 2023, 16(7), 9859-9872. doi: 10.1007/s12274-023-5742-7
  50. Shi, S.; Fu, W.; Lin, S.; Tian, T.; Li, S.; Shao, X.; Zhang, Y.; Zhang, T.; Tang, Z.; Zhou, Y.; Lin, Y.; Cai, X. Targeted and effective glioblastoma therapy via aptamer-modified tetrahedral framework nucleic acid-paclitaxel nanoconjugates that can pass the blood brain barrier. Nanomedicine , 2019, 21, 102061. doi: 10.1016/j.nano.2019.102061 PMID: 31344499
  51. Esposito, C.L.; Nuzzo, S.; Ibba, M.L.; Ricci-Vitiani, L.; Pallini, R.; Condorelli, G.; Catuogno, S.; de Franciscis, V. Combined targeting of glioblastoma stem-like cells by neutralizing RNA-bio-drugs for STAT3. Cancers , 2020, 12(6), 1434. doi: 10.3390/cancers12061434 PMID: 32486489
  52. Yoon, S.; Wu, X.; Armstrong, B.; Habib, N.; Rossi, J.J. An RNA aptamer targeting the receptor tyrosine kinase PDGFRα induces anti-tumor effects through STAT3 and p53 in glioblastoma. Mol. Ther. Nucleic Acids, 2019, 14, 131-141. doi: 10.1016/j.omtn.2018.11.012 PMID: 30594071
  53. Anton, J.; Sudibio, S.; Handoko, H.; Permata, T.; Kodrat, H.; Nuryadi, E.; Sofyan, H.; Susanto, E.; Mulyadi, R.; Aman, R.; Gondhowiardjo, S. Overexpression of c-Met is associated with poor prognosis in glioblastoma multiforme: A systematic review and meta-analyses. Asian Pac. J. Cancer Prev., 2021, 22(10), 3075-3080. doi: 10.31557/APJCP.2021.22.10.3075 PMID: 34710981
  54. Zhang, X.; Liang, H.; Tan, Y.; Wu, X.; Li, S.; Shi, Y.A. U87-EGFRvIII cell-specific aptamer mediates small interfering RNA delivery. Biomed. Rep., 2014, 2(4), 495-499. doi: 10.3892/br.2014.276 PMID: 24944794
  55. Esposito, C.L.; Nuzzo, S.; Kumar, S.A.; Rienzo, A.; Lawrence, C.L.; Pallini, R.; Shaw, L.; Alder, J.E.; Ricci-Vitiani, L.; Catuogno, S.; de Franciscis, V. A combined microRNA-based targeted therapeutic approach to eradicate glioblastoma stem-like cells. J. Control. Release, 2016, 238, 43-57. doi: 10.1016/j.jconrel.2016.07.032 PMID: 27448441
  56. Vermeer, A.W.P.; Norde, W. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys. J., 2000, 78(1), 394-404. doi: 10.1016/S0006-3495(00)76602-1 PMID: 10620303
  57. Papademetriou, I.T.; Porter, T. Promising approaches to circumvent the blood-brain barrier: Progress, pitfalls and clinical prospects in brain cancer. Ther. Deliv., 2015, 6(8), 989-1016. doi: 10.4155/tde.15.48 PMID: 26488496
  58. Zhou, G.; Latchoumanin, O.; Hebbard, L.; Duan, W.; Liddle, C.; George, J.; Qiao, L. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers. Adv. Drug Deliv. Rev., 2018, 134, 107-121. doi: 10.1016/j.addr.2018.04.005 PMID: 29627370
  59. Song, Y.; Zhu, Z.; An, Y.; Zhang, W.; Zhang, H.; Liu, D.; Yu, C.; Duan, W.; Yang, C.J. Selection of DNA aptamers against epithelial cell adhesion molecule for cancer cell imaging and circulating tumor cell capture. Anal. Chem., 2013, 85(8), 4141-4149. doi: 10.1021/ac400366b PMID: 23480100
  60. He, F.; Xiong, Y.; Liu, J.; Tong, F.; Yan, D. Construction of Au-IDE/CFP10-ESAT6 aptamer/DNA-AuNPs MSPQC for rapid detection of Mycobacterium tuberculosis. Biosens. Bioelectron., 2016, 77, 799-804. doi: 10.1016/j.bios.2015.10.054 PMID: 26513286
  61. Keefe, A.D.; Pai, S.; Ellington, A. Aptamers as therapeutics. Nat. Rev. Drug Discov., 2010, 9(7), 537-550. doi: 10.1038/nrd3141 PMID: 20592747
  62. Lollo, B.; Steele, F.; Gold, L. Beyond antibodies: New affinity reagents to unlock the proteome. Proteomics, 2014, 14(6), 638-644. doi: 10.1002/pmic.201300187 PMID: 24395722
  63. Bukari, B.; Samarasinghe, R.M.; Noibanchong, J.; Shigdar, S.L. Non-invasive delivery of therapeutics into the brain: the potential of aptamers for targeted delivery. Biomedicines, 2020, 8(5), 120. doi: 10.3390/biomedicines8050120 PMID: 32422973
  64. Uribe, M.L.; Marrocco, I.; Yarden, Y. EGFR in cancer: Signaling mechanisms, drugs, and acquired resistance. Cancers , 2021, 13(11), 2748. doi: 10.3390/cancers13112748 PMID: 34206026
  65. Díaz-Serrano, A.; Gella, P.; Jiménez, E.; Zugazagoitia, J.; Paz-Ares Rodríguez, L. Targeting EGFR in lung cancer: Current standards and developments. Drugs, 2018, 78(9), 893-911. doi: 10.1007/s40265-018-0916-4 PMID: 29915896
  66. Li, F.; Wu, H.; Du, X.; Sun, Y.; Rausseo, B.N.; Talukder, A.; Katailiha, A.; Elzohary, L.; Wang, Y.; Wang, Z.; Lizée, G. Epidermal growth factor receptor-targeted neoantigen peptide vaccination for the treatment of non-small cell lung cancer and glioblastoma. Vaccines , 2023, 11(9), 1460. doi: 10.3390/vaccines11091460 PMID: 37766136
  67. Zhang, Z.; Lu, M.; Qin, Y.; Gao, W.; Tao, L.; Su, W.; Zhong, J. Neoantigen: A new breakthrough in tumor immunotherapy. Front. Immunol., 2021, 12, 672356. doi: 10.3389/fimmu.2021.672356 PMID: 33936118
  68. Naeimi, R.; Bahmani, A.; Afshar, S. Investigating the role of peptides in effective therapies against cancer. Cancer Cell Int., 2022, 22(1), 139. doi: 10.1186/s12935-022-02553-7 PMID: 35346211
  69. Battaglia, S. Neoantigen prediction from genomic and transcriptomic data. Methods Enzymol; , 2020, 635, pp. 267-281. doi: 10.1016/bs.mie.2019.10.003 PMID: 32122550
  70. Yamada, T.; Azuma, K.; Muta, E.; Kim, J.; Sugawara, S.; Zhang, G.L.; Matsueda, S.; Kasama-Kawaguchi, Y.; Yamashita, Y.; Yamashita, T.; Nishio, K.; Itoh, K.; Hoshino, T.; Sasada, T. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation. PLoS One, 2013, 8(11), e78389. doi: 10.1371/journal.pone.0078389 PMID: 24223798
  71. Ofuji, K.; Tada, Y.; Yoshikawa, T.; Shimomura, M.; Yoshimura, M.; Saito, K.; Nakamoto, Y.; Nakatsura, T. A peptide antigen derived from EGFR T790M is immunogenic in non-small cell lung cancer. Int. J. Oncol., 2015, 46(2), 497-504. doi: 10.3892/ijo.2014.2787 PMID: 25532027
  72. Akazawa, Y.; Saito, Y.; Yoshikawa, T.; Saito, K.; Nosaka, K.; Shimomura, M.; Mizuno, S.; Nakamoto, Y.; Nakatsura, T. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non–small cell lung cancer. Cancer Sci., 2020, 111(8), 2736-2746. doi: 10.1111/cas.14451 PMID: 32391625
  73. Dimou, A.; Grewe, P.; Sidney, J.; Sette, A.; Norman, P.J.; Doebele, R.C. HLA class I binding of mutant EGFR peptides in NSCLC is associated with improved survival. J. Thorac. Oncol., 2021, 16(1), 104-112. doi: 10.1016/j.jtho.2020.08.023 PMID: 32927123
  74. Li, F.; Deng, L.; Jackson, K.R.; Talukder, A.H.; Katailiha, A.S.; Bradley, S.D.; Zou, Q.; Chen, C.; Huo, C.; Chiu, Y.; Stair, M.; Feng, W.; Bagaev, A.; Kotlov, N.; Svekolkin, V.; Ataullakhanov, R.; Miheecheva, N.; Frenkel, F.; Wang, Y.; Zhang, M.; Hawke, D.; Han, L.; Zhou, S.; Zhang, Y.; Wang, Z.; Decker, W.K.; Sonnemann, H.M.; Roszik, J.; Forget, M.A.; Davies, M.A.; Bernatchez, C.; Yee, C.; Bassett, R.; Hwu, P.; Du, X.; Lizee, G. Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J. Immunother. Cancer, 2021, 9(7), e002531. doi: 10.1136/jitc-2021-002531 PMID: 34244308
  75. Ebben, J.D.; Lubet, R.A.; Gad, E.; Disis, M.L.; You, M. Epidermal growth factor receptor derived peptide vaccination to prevent lung adenocarcinoma formation: An in vivo study in a murine model of EGFR mutant lung cancer. Mol. Carcinog., 2016, 55(11), 1517-1525. doi: 10.1002/mc.22405 PMID: 26346412
  76. Weller, M.; Butowski, N.; Tran, D.D.; Recht, L.D.; Lim, M.; Hirte, H.; Ashby, L.; Mechtler, L.; Goldlust, S.A.; Iwamoto, F.; Drappatz, J.; O’Rourke, D.M.; Wong, M.; Hamilton, M.G.; Finocchiaro, G.; Perry, J.; Wick, W.; Green, J.; He, Y.; Turner, C.D.; Yellin, M.J.; Keler, T.; Davis, T.A.; Stupp, R.; Sampson, J.H.; Butowski, N.; Campian, J.; Recht, L.; Lim, M.; Ashby, L.; Drappatz, J.; Hirte, H.; Iwamoto, F.; Mechtler, L.; Goldlust, S.; Becker, K.; Barnett, G.; Nicholas, G.; Desjardins, A.; Benkers, T.; Wagle, N.; Groves, M.; Kesari, S.; Horvath, Z.; Merrell, R.; Curry, R.; O’Rourke, J.; Schuster, D.; Wong, M.; Mrugala, M.; Jensen, R.; Trusheim, J.; Lesser, G.; Belanger, K.; Sloan, A.; Purow, B.; Fink, K.; Raizer, J.; Schulder, M.; Nair, S.; Peak, S.; Perry, J.; Brandes, A.; Weller, M.; Mohile, N.; Landolfi, J.; Olson, J.; Finocchiaro, G.; Jennens, R.; DeSouza, P.; Robinson, B.; Crittenden, M.; Shih, K.; Flowers, A.; Ong, S.; Connelly, J.; Hadjipanayis, C.; Giglio, P.; Mott, F.; Mathieu, D.; Lessard, N.; Sepulveda, S.J.; Lövey, J.; Wheeler, H.; Inglis, P-L.; Hardie, C.; Bota, D.; Lesniak, M.; Portnow, J.; Frankel, B.; Junck, L.; Thompson, R.; Berk, L.; McGhie, J.; Macdonald, D.; Saran, F.; Soffietti, R.; Blumenthal, D. André de, S.B.C.M.; Nowak, A.; Singhal, N.; Hottinger, A.; Schmid, A.; Srkalovic, G.; Baskin, D.; Fadul, C.; Nabors, L.; LaRocca, R.; Villano, J.; Paleologos, N.; Kavan, P.; Pitz, M.; Thiessen, B.; Idbaih, A.; Frenel, J.S.; Domont, J.; Grauer, O.; Hau, P.; Marosi, C.; Sroubek, J.; Hovey, E.; Sridhar, P.S.; Cher, L.; Dunbar, E.; Coyle, T.; Raymond, J.; Barton, K.; Guarino, M.; Raval, S.; Stea, B.; Dietrich, J.; Hopkins, K.; Erridge, S.; Steinbach, J-P.; Pineda, L.E.; Balana, Q.C.; Sonia del, B.B.; Wenczl, M.; Molnár, K.; Hideghéty, K.; Lossos, A.; Myra van, L.; Levy, A.; Harrup, R.; Patterson, W.; Lwin, Z.; Sathornsumetee, S.; Lee, E-J.; Ho, J-T.; Emmons, S.; Duic, J.P.; Shao, S.; Ashamalla, H.; Weaver, M.; Lutzky, J.; Avgeropoulos, N.; Hanna, W.; Nadipuram, M.; Cecchi, G.; O’Donnell, R.; Pannullo, S.; Carney, J.; Hamilton, M.; MacNeil, M.; Beaney, R.; Fabbro, M.; Schnell, O.; Fietkau, R.; Stockhammer, G.; Malinova, B.; Odrazka, K.; Sames, M.; Miguel Gil, G.; Razis, E.; Lavrenkov, K.; Castro, G.; Ramirez, F.; Baldotto, C.; Viola, F.; Malheiros, S.; Lickliter, J.; Gauden, S.; Dechaphunkul, A.; Thaipisuttikul, I.; Thotathil, Z.; Ma, H-I.; Cheng, W-Y.; Chang, C-H.; Salas, F.; Dietrich, P-Y.; Mamot, C.; Nayak, L.; Nag, S. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial. Lancet Oncol., 2017, 18(10), 1373-1385. doi: 10.1016/S1470-2045(17)30517-X PMID: 28844499
  77. Wu, A.; Xiao, J.; Anker, L.; Hall, W.A.; Gregerson, D.S.; Cavenee, W.K.; Chen, W.; Low, W.C. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J. Neurooncol., 2006, 76(1), 23-30. doi: 10.1007/s11060-005-3280-7 PMID: 16155724
  78. Ellingson, B.M.; Chung, C.; Pope, W.B.; Boxerman, J.L.; Kaufmann, T.J. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J. Neurooncol., 2017, 134(3), 495-504. doi: 10.1007/s11060-017-2375-2 PMID: 28382534
  79. Zhang, Z.; Chen, X.; Yuan, T. Precision radiotherapy for nasopharyngeal carcinoma. Precis. Radiat. Oncol., 2024, 8(1), 37-41. doi: 10.1002/pro6.1219
  80. Yartsev, S.; Kron, T.; Van Dyk, J. Tomotherapy as a tool in imageguided radiation therapy (IGRT): Theoretical and technological aspects. Biomed. Imaging Interv. J.,, 3(1), e16.2007, doi: 10.2349/biij.3.1.e16
  81. Toms, S.A.; Kim, C.Y.; Nicholas, G.; Ram, Z. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: A subgroup analysis of the EF-14 phase III trial. J. Neurooncol., 2019, 141(2), 467-473. doi: 10.1007/s11060-018-03057-z PMID: 30506499
  82. Kesari, S.; Ram, Z. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: A post hoc analysis of the EF-14 trial. CNS Oncol., 2017, 6(3), 185-193. doi: 10.2217/cns-2016-0049 PMID: 28399638
  83. Stupp, R.; Taillibert, S.; Kanner, A.; Read, W.; Steinberg, D.M.; Lhermitte, B.; Toms, S.; Idbaih, A.; Ahluwalia, M.S.; Fink, K.; Di Meco, F.; Lieberman, F.; Zhu, J.J.; Stragliotto, G.; Tran, D.D.; Brem, S.; Hottinger, A.F.; Kirson, E.D.; Lavy-Shahaf, G.; Weinberg, U.; Kim, C.Y.; Paek, S.H.; Nicholas, G.; Bruna, J.; Hirte, H.; Weller, M.; Palti, Y.; Hegi, M.E.; Ram, Z. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA, 2017, 318(23), 2306-2316. doi: 10.1001/jama.2017.18718 PMID: 29260225
  84. Zhu, J.J.; Demireva, P.; Kanner, A.A.; Pannullo, S.; Mehdorn, M.; Avgeropoulos, N.; Salmaggi, A.; Silvani, A.; Goldlust, S.; David, C.; Benouaich-Amiel, A. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. J. Neurooncol., 2017, 135(3), 545-552. doi: 10.1007/s11060-017-2601-y PMID: 28849310
  85. Li, X.; Liu, K.; Xing, L.; Rubinsky, B. A review of tumor treating fields (TTFields): Advancements in clinical applications and mechanistic insights. Radiol. Oncol., 2023, 57(3), 279-291. doi: 10.2478/raon-2023-0044 PMID: 37665740
  86. Rominiyi, O.; Vanderlinden, A.; Clenton, S.J.; Bridgewater, C.; Al-Tamimi, Y.; Collis, S.J. Tumour treating fields therapy for glioblastoma: Current advances and future directions. Br. J. Cancer, 2021, 124(4), 697-709. doi: 10.1038/s41416-020-01136-5 PMID: 33144698
  87. Mun, E.J.; Babiker, H.M.; Weinberg, U.; Kirson, E.D.; Von Hoff, D.D. Tumor-treating fields: A fourth modality in cancer treatment. Clin. Cancer Res., 2018, 24(2), 266-275. doi: 10.1158/1078-0432.CCR-17-1117 PMID: 28765323
  88. Colamaria, A.; Leone, A.; Fochi, N.P.; Di Napoli, V.; Giordano, G.; Landriscina, M.; Patel, K.; Carbone, F. Tumor treating fields for the treatment of glioblastoma: Current understanding and future perspectives. Surg. Neurol. Int., 2023, 14, 394. doi: 10.25259/SNI_674_2023 PMID: 38053701
  89. Weller, M.; Le Rhun, E.; Preusser, M.; Tonn, J.C.; Roth, P. How we treat glioblastoma. ESMO Open, 2019, 4(Suppl. 2), e000520. doi: 10.1136/esmoopen-2019-000520 PMID: 31297242
  90. Goetz, L.H.; Schork, N. J. Personalized medicine: Motivation, challenges, and progress. Fertil. Steril., 2018, 109(6), 952-963. doi: 10.1016/j.fertnstert.2018.05.006 PMID: 29935653
  91. Mouliere, F.; Smith, C.G.; Heider, K.; Su, J.; van der Pol, Y.; Thompson, M.; Morris, J.; Wan, J.C.M.; Chandrananda, D.; Hadfield, J.; Grzelak, M.; Hudecova, I.; Couturier, D.L.; Cooper, W.; Zhao, H.; Gale, D.; Eldridge, M.; Watts, C.; Brindle, K.; Rosenfeld, N.; Mair, R. Fragmentation patterns and personalized sequencing of cell‐free DNA in urine and plasma of glioma patients. EMBO Mol. Med., 2021, 13(8), e12881. doi: 10.15252/emmm.202012881 PMID: 34291583
  92. Mair, R.; Mouliere, F. Cell-free DNA technologies for the analysis of brain cancer. Br. J. Cancer, 2022, 126(3), 371-378. doi: 10.1038/s41416-021-01594-5 PMID: 34811503
  93. Gousias, K.; Theocharous, T.; Simon, M. Mechanisms of cell cycle arrest and apoptosis in glioblastoma. Biomedicines, 2022, 10(3), 564. doi: 10.3390/biomedicines10030564 PMID: 35327366
  94. Kreatsoulas, D.; Bolyard, C.; Wu, B.X.; Cam, H.; Giglio, P.; Li, Z. Translational landscape of glioblastoma immunotherapy for physicians: Guiding clinical practice with basic. J. Hematol. Oncol., 2022, 15(1), 80. doi: 10.1186/s13045-022-01298-0
  95. Sunil, K.G.; Joshi, A.; Kaushik, V. Bioinformatics in personalized medicine. In: Advances in Bioinformatics; Singh, V.; Kumar, A., Eds.; Springer: Singapore, 2021; pp. 303-315.
  96. Ratliff, M.; Kim, H.; Qi, H.; Kim, M.; Ku, B.; Azorin, D.D.; Hausmann, D.; Khajuria, R.K.; Patel, A.; Maier, E.; Cousin, L.; Ogier, A.; Sahm, F.; Etminan, N.; Bunse, L.; Winkler, F.; El-Khoury, V.; Platten, M.; Kwon, Y.J. Patient-derived tumor organoids for guidance of personalized drug therapies in recurrent glioblastoma. Int. J. Mol. Sci., 2022, 23(12), 6572. doi: 10.3390/ijms23126572 PMID: 35743016
  97. Chi, A.S.; Cahill, D.P.; Reardon, D.A.; Wen, P.Y.; Mikkelsen, T.; Peereboom, D.M. xploring predictors of response to dacomitinib in EGFR-Amplified recurrent glioblastoma. JCO Precis Oncol., 2020, 202, , 19.00295. PMID: 32923886
  98. Frenel, J-S.; Cartron, P-F.; Gourmelon, C.; Campion, L.; Aumont, M.; Augereau, P.; Ducray, F.; Loussouarn, D.; Lallier, L.; Robert, M.; Campone, M. 370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma. Ann. Oncol., 2020, 31, S400. doi: 10.1016/j.annonc.2020.08.479
  99. Kessler, T.; Berberich, A.; Casalini, B.; Drüschler, K.; Ostermann, H.; Dormann, A.; Walter, S.; Hai, L.; Schlesner, M.; Herold-Mende, C.; Jungk, C.; Unterberg, A.; Bendszus, M.; Sahm, K.; von Deimling, A.; Winkler, F.; Platten, M.; Wick, W.; Sahm, F.; Wick, A. Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma. Neurooncol. Adv., 2020, 2(1), vdz060. doi: 10.1093/noajnl/vdz060 PMID: 32642725
  100. Lombardi, G.; Barresi, V.; Indraccolo, S.; Simbolo, M.; Fassan, M.; Mandruzzato, S.; Simonelli, M.; Caccese, M.; Pizzi, M.; Fassina, A.; Padovan, M.; Masetto, E.; Gardiman, M.P.; Bonavina, M.G.; Caffo, M.; Persico, P.; Chioffi, F.; Denaro, L.; Dei Tos, A.P.; Scarpa, A.; Zagonel, V. Pembrolizumab activity in recurrent high-grade gliomas with partial or complete loss of mismatch repair protein expression: A monocentric, observational and prospective pilot study. Cancers , 2020, 12(8), 2283. doi: 10.3390/cancers12082283 PMID: 32823925
  101. Mishinov, S.V.; Budnik, A.Y.; Stupak, V.V.; Leplina, O.Y.; Tyrinova, T.V.; Ostanin, A.A.; Chernykh, E.R. Autologous and pooled tumor lysates in combined immunotherapy of patients with glioblastoma. Sovrem. Tekhnologii Med., 2020, 12(2), 34-41. doi: 10.17691/stm2020.12.2.04 PMID: 34513051
  102. Reardon, D.A.; Desjardins, A.; Vredenburgh, J.J.; O’Rourke, D.M.; Tran, D.D.; Fink, K.L.; Nabors, L.B.; Li, G.; Bota, D.A.; Lukas, R.V.; Ashby, L.S.; Duic, J.P.; Mrugala, M.M.; Cruickshank, S.; Vitale, L.; He, Y.; Green, J.A.; Yellin, M.J.; Turner, C.D.; Keler, T.; Davis, T.A.; Sampson, J.H. Rindopepimut with Bevacizumab for patients with relapsed EGFRvIII-expressing glioblastoma (ReACT): Results of a double-blind randomized phase II trial. Clin. Cancer Res., 2020, 26(7), 1586-1594. doi: 10.1158/1078-0432.CCR-18-1140 PMID: 32034072
  103. Rudnick, J.D.; Sarmiento, J.M.; Uy, B.; Nuno, M.; Wheeler, C.J.; Mazer, M.J.; Wang, H.; Hu, J.L.; Chu, R.M.; Phuphanich, S.; Black, K.L.; Yu, J.S. A phase I trial of surgical resection with Gliadel Wafer placement followed by vaccination with dendritic cells pulsed with tumor lysate for patients with malignant glioma. J. Clin. Neurosci., 2020, 74, 187-193. doi: 10.1016/j.jocn.2020.03.006 PMID: 32169363
  104. Sampson, J.H.; Achrol, A.; Aghi, M.K.; Bankiewicz, K.; Bexon, M.; Brem, S.; Brenner, A.J.; Chandhasin, C.; Chowdhary, S.A.; Coello, M.; Das, S.; Han, S.J.; Kesari, S.; Merchant, F.; Merchant, N.; Randazzo, D.; Vogelbaum, M.A.; Vrionis, F.; Zabek, M.; Butowski, N.A. MDNA55 survival in recurrent glioblastoma (rGBM) patients expressing the interleukin-4 receptor (IL4R) as compared to a matched synthetic control. J. Clin. Oncol., 2020, 38(15)(suppl.), 2513-2513. doi: 10.1200/JCO.2020.38.15_suppl.2513
  105. Smith, C.; Lineburg, K.E.; Martins, J.P.; Ambalathingal, G.R.; Neller, M.A.; Morrison, B.; Matthews, K.K.; Rehan, S.; Crooks, P.; Panikkar, A.; Beagley, L.; Le Texier, L.; Srihari, S.; Walker, D.; Khanna, R. Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. J. Clin. Invest., 2020, 130(11), 6041-6053. doi: 10.1172/JCI138649 PMID: 32750039
  106. Van Den Bent, M.; Eoli, M.; Sepulveda, J.M.; Smits, M.; Walenkamp, A.; Frenel, J.S.; Franceschi, E.; Clement, P.M.; Chinot, O.; De Vos, F.; Whenham, N.; Sanghera, P.; Weller, M.; Dubbink, H.J.; French, P.; Looman, J.; Dey, J.; Krause, S.; Ansell, P.; Nuyens, S.; Spruyt, M.; Brilhante, J.; Coens, C.; Gorlia, T.; Golfinopoulos, V. INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma. Neuro-oncol., 2020, 22(5), 684-693. doi: 10.1093/neuonc/noz222 PMID: 31747009
  107. Wang, Q.T.; Nie, Y.; Sun, S.N.; Lin, T.; Han, R.J.; Jiang, J.; Li, Z.; Li, J.Q.; Xiao, Y.P.; Fan, Y.Y.; Yuan, X.H.; Zhang, H.; Zhao, B.B.; Zeng, M.; Li, S.Y.; Liao, H.X.; Zhang, J.; He, Y.W. Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. Cancer Immunol. Immunother., 2020, 69(7), 1375-1387. doi: 10.1007/s00262-020-02496-w PMID: 32078016
  108. Bonneville-Levard, A.; Frappaz, D.; Tredan, O.; Lavergne, E.; Corset, V.; Agrapart, V.; Chabaud, S.; Pissaloux, D.; Wang, Q.; Attignon, V.; Cartalat, S.; Ducray, F.; Thomas-Maisonneuve, L.; Honnorat, J.; Meyronet, D.; Taillandier, L.; Blonski, M.; Viari, A.; Baudet, C.; Sohier, E.; Lantuejoul, S.; Paindavoine, S.; Treilleux, I.; Rodriguez, C.; Pérol, D.; Blay, J.Y. Molecular profile to guide personalized medicine in adult patients with primary brain tumors: Results from the ProfiLER trial. Med. Oncol., 2022, 39(1), 4. doi: 10.1007/s12032-021-01536-4 PMID: 34739635
  109. Cardona, A.F.; Jaramillo-Velásquez, D.; Ruiz-Patiño, A.; Polo, C.; Jiménez, E.; Hakim, F.; Gómez, D.; Ramón, J.F.; Cifuentes, H.; Mejía, J.A.; Salguero, F.; Ordoñez, C.; Muñoz, Á.; Bermúdez, S.; Useche, N.; Pineda, D.; Ricaurte, L.; Zatarain-Barrón, Z.L.; Rodríguez, J.; Avila, J.; Rojas, L.; Jaller, E.; Sotelo, C.; Garcia-Robledo, J.E.; Santoyo, N.; Rolfo, C.; Rosell, R.; Arrieta, O. Efficacy of osimertinib plus bevacizumab in glioblastoma patients with simultaneous EGFR amplification and EGFRvIII mutation. J. Neurooncol., 2021, 154(3), 353-364. doi: 10.1007/s11060-021-03834-3 PMID: 34498213
  110. Padovan, M.; Eoli, M.; Pellerino, A.; Rizzato, S.; Caserta, C.; Simonelli, M.; Michiara, M.; Caccese, M.; Anghileri, E.; Cerretti, G.; Rudà, R.; Zagonel, V.; Lombardi, G. Depatuxizumab Mafodotin (Depatux-M) plus temozolomide in recurrent glioblastoma patients: Real-world experience from a multicenter study of Italian Association of Neuro-Oncology (AINO). Cancers , 2021, 13(11), 2773. doi: 10.3390/cancers13112773 PMID: 34204877
  111. Werlenius, K.; Stragliotto, G.; Strandeus, M.; Blomstrand, M.; Carén, H.; Jakola, A.S.; Rydenhag, B.; Dyregaard, D.; Dzhandzhugazyan, K.N.; Kirkin, A.F.; Raida, M.K.; Smits, A.; Kinhult, S. A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma. Neurooncol. Adv., 2021, 3(1), vdab156. doi: 10.1093/noajnl/vdab156 PMID: 34765977
  112. Ciesielski, M.J.; Ahluwalia, M.S.; Reardon, D.A.; Abad, A.P.; Curry, W.T.; Wong, E.T.; Peereboom, D.M.; Figel, S.A.; Hutson, A.; Groman, A.; Withers, H.G.; Liu, S.; Belal, A.; Qiu, J-X.; Mogensen, K.; Schilero, C.; Casucci, D.M.; Mechtler, L.; Fenstermaker, R.A. Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma. J. Clin. Oncol., 2022, 40(16)(Suppl.), 2037. doi: 10.1200/JCO.2022.40.16_suppl.2037
  113. Hu, J.L.; Omofoye, O.A.; Rudnick, J.D.; Kim, S.; Tighiouart, M.; Phuphanich, S.; Wang, H.; Mazer, M.; Ganaway, T.; Chu, R.M.; Patil, C.G.; Black, K.L.; Shiao, S.L.; Wang, R.; Yu, J.S. A phase I study of autologous dendritic cell vaccine pulsed with allogeneic stem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma. Clin. Cancer Res., 2022, 28(4), 689-696. doi: 10.1158/1078-0432.CCR-21-2867 PMID: 34862245
  114. Kasenda, B.; König, D.; Manni, M.; Ritschard, R.; Duthaler, U.; Bartoszek, E.; Bärenwaldt, A.; Deuster, S.; Hutter, G.; Cordier, D.; Mariani, L.; Hench, J.; Frank, S.; Krähenbühl, S.; Zippelius, A.; Rochlitz, C.; Mamot, C.; Wicki, A.; Läubli, H. Targeting immunoliposomes to EGFR-positive glioblastoma. ESMO Open, 2022, 7(1), 100365. doi: 10.1016/j.esmoop.2021.100365 PMID: 34998092
  115. Van Gool, S.W.; Makalowski, J.; Bitar, M.; Van de Vliet, P.; Schirrmacher, V.; Stuecker, W. Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients. Genes Immun., 2022, 23(8), 255-259. doi: 10.1038/s41435-022-00162-y PMID: 35173295

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bentham Science Publishers, 2025